
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical lotion containing mometasone furoate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing mometasone are listed in lotion, spray, ointment, cream, aerosol and solution forms.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Mometasone furoate is a medium-potency topical corticosteroid that compounding pharmacies prepare as creams, ointments, lotions and solutions by prescription.
Mometasone furoate is a synthetic corticosteroid. Applied to the skin, it enters cells and switches on anti-inflammatory proteins, including lipocortins, which calm the redness, swelling and itch of inflamed skin and narrow small blood vessels. Among topical steroids it sits in the medium-potency range, and only about 0.4 percent of an applied dose reaches the bloodstream through intact skin. Manufactured mometasone furoate cream, ointment and lotion (originally Elocon, now generics) are FDA-approved for relief of the inflammatory and itchy manifestations of corticosteroid-responsive dermatoses in patients two years and older. A prescriber might order compounded mometasone for a vehicle not manufactured, a base free of a preservative or lanolin a patient reacts to, or a combination with another topical ingredient in a single preparation. Compounded preparations are not FDA-approved and require a prescription.
Mometasone is for the skin only; keep it out of the eyes and mouth, and do not use it if you have reacted to it before. Avoid the face, groin and skin folds unless directed, and do not cover treated skin with bandages, plastic or diapers, which drive more steroid into the body. Enough can be absorbed, especially in children or over large areas, to suppress the adrenal glands, raise blood sugar or cause Cushing's syndrome. Topical steroids have been linked to cataracts and glaucoma; report any vision change. Common local effects are burning, itching, thinning skin, stretch marks and color change. Tell your prescriber about every steroid you use. Use in pregnancy only if clearly needed; LactMed considers short courses unlikely to harm a breastfed infant but says to keep the infant's skin away from treated areas. If side effects bother you, talk to your prescriber or pharmacist.
Mometasone furoate is a 17-heterocyclic corticosteroid with anti-inflammatory, antipruritic and vasoconstrictive activity; the label attributes the effect to induction of lipocortins that inhibit phospholipase A2. Percutaneous absorption is about 0.4 percent of the applied dose over eight hours on intact unoccluded skin and higher on inflamed skin or under occlusion. Potency is medium (groups IV to V in the AAFP classification). Labeled indication for mometasone furoate cream, ointment and lotion (generics; Elocon brand discontinued): inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, age two and older; the label limits pediatric use to three weeks and advises against diaper-area use. In a pediatric study of extensive application, adrenal suppression occurred in about 16 percent of subjects. No drug interaction studies have been conducted. Prescribers select the vehicle for the lesion type per AAFP guidance (ointments for dry hyperkeratotic plaques, creams for weeping or intertriginous skin, lotions for hairy areas); strength and duration are per prescriber. Monitoring: local atrophy, striae and telangiectasia, allergic contact dermatitis presenting as failure to heal, and HPA axis evaluation (cortisol or ACTH stimulation) when large areas, occlusion or prolonged use are involved. Tachyphylaxis can develop with continuous use. Not a controlled substance.
Wash your hands. Shake the bottle if your label says to. Apply a thin layer to clean, dry skin and rub in gently until it disappears. Let it dry before dressing. Avoid the eyes and broken skin unless your prescriber directs otherwise. Wash your hands afterward.
Lotions are aqueous. Under USP <795>, a preserved lotion usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Keep the bottle closed, away from heat, keep from freezing, keep out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)